Accessible at https://doi.org/10.1177/26330040231188979, the Chrysalis Task Force identified key financial and non-financial factors that make rare disease research and development attractive to companies.
More information on the Chrysalis Task Force here: https://irdirc.org/chrysalis-project/
« It was a real pleasure working with such a talented IRDiRC Task Force. We also truly appreciate the critical input provided by the survey and interview respondents. All of them provided specific yet nuanced responses that were framed in an important general context. Their responses allowed the Task Force to compose and frame what I consider to be an extremely informative report. » says Adam L. Hartman, MD, Co-chair of the Chrysalis Task Force and Program Director at the National Institute of Neurological Disorders and Stroke (NINDS) part of U.S. National Institutes of Health (NIH)